BBSome complex that includes BBS1, BBS2, BBS4, BBS5, BBS7, BBS8, and BBS9. Proteins in this complex are thought to be involved in ciliogenesis, because of their function in membrane trafficking in the primary cilium [20] .
The current study was designed to find the molecular basis of BBS in two Pakistani families (families A and B) using exome sequencing. A novel splice donor site mutation c.47+1G>T in BBS1 was identified in family A, and a previously reported BBS1 mutation, c.442G>A; p.(Asp148Asn) [21] , was identified in family B.
METHODS

Ethics committee/institutional review board approval:
Approval for this study was granted by the ethics committee/ institutional review board of Shifa College of Medicine, Shifa International Hospital, Islamabad. Written informed consent was obtained from both families before the study began. In addition, the study conformed to the tenets of the Declaration of Helsinki.
Clinical examination: Clinical examination included ophthalmic examination, electroretinography, echocardiography, liver function tests, and renal profiling. Blood glucose was also measured to determine the presence or absence of diabetes mellitus.
Blood sampling and DNA preparation: Both families ( Figure  1A ,B) were recruited from the central part of Punjab. Venous blood of affected and normal individuals of both families was drawn by venipuncture and collected in acid citrate dextrose vacutainers (Becton Dickinson, Franklin Lakes, NJ). DNA was extracted with a standard phenol-chloroform extraction procedure [22] . Briefly, it consisted of the lysis of white blood cells, followed by protein digestion, extraction of the DNA with phenol-chloroform, and precipitation of DNA with isopropanol.
Exome sequencing: Probands of each family were selected for exome sequencing, which was performed on a 5500XL sequencing platform from Life Technologies (Carlsbad, CA). The exomes of the probands were enriched according to the manufacturer's protocol using the SureSelect Human All Exon v2 Kit (50 Mb), containing the exonic sequences of approximately 21,000 genes from Agilent Technologies, Inc. (Santa Clara, CA). LifeScope software v2.1 from Life Technologies (Carlsbad, CA) was used to map color space reads along the hg19 reference genome assembly. The DiBayes algorithm, with high-stringency calling, was used for single-nucleotide variant calling. The small Indel Tool was used to detect small insertions and deletions. Exome sequencing data were filtered as described previously [23, 24] . Briefly, the variants in known BBS genes were selected and analyzed for segregation in the families.
Sequence analysis: Variants identified with exome sequencing were confirmed with Sanger sequencing using an automated DNA sequencing machine (3730 DNA analyzer; Applied Biosystems, Inc., Foster City, CA). PCR primers were designed with the help of the online tool Primer3 [25] .
Splice site prediction: NetGene2 World Wide Web Server [26, 27] , an online splice site prediction program, was used to predict the effect of sequence variants located in or near the splice sites.
In silico pathogenicity assessment of missense variant: Pathogenicity of the missense variant was assessed using the online prediction tools polymorphism phenotyping v-2 (PolyPhen-2) and sorting intolerant from tolerant (SIFT). In addition, the HOPE server was used to predict structural consequences in the mutant protein using normal protein structure with accession number Q8NFJ9 [28] .
RESULTS
Clinical findings:
Affected individuals underwent extensive clinical examination, including fundus examination, which revealed the presence of bone spicules and attenuation of blood vessels (Figure 2 ). Electroretinography measurements were recorded for affected individual IV:5 of family A only, which showed reduced scotopic and photopic electrophysiological responses in the patient compared to a normal individual (Table 1 ). All other primary and secondary BBS features were also investigated ( Table 2) . Retinitis pigmentosa, obesity, and learning difficulties were present in all affected individuals while polydactyly was present in the affected woman (IV:4) of family A and affected individuals IV:3 and IV:5 of family B. Developmental delay, a secondary feature of BBS, was also observed in both families. Echocardiography was normal in both affected individuals of family A whereas in family B echocardiography was not performed, but affected individuals of family B were hypertensive. Liver function was also normal, and no renal defects were observed in either family. Affected individuals of family B also had intellectual disability and dental crowding. All patients fulfilled the diagnostic criteria of BBS having at least four primary or three primary and two secondary BBS features.
Genetic findings:
To identify the pathogenic mutation, the exome data sequence variants were filtered to reduce the number of potentially pathogenic variants. First, we searched for variants present in known BBS genes. In both families, variants were found in six BBS genes, including BBS1, BBS2, BBS4, BBS7, BBS9, and BBS12 (Table 3 ). The frequency of the variants identified in known BBS genes, except the BBS1 variants described below, ranged from 13% to 99% in an in-house database.
In family A, a novel splice donor site mutation (c.47+1G>T) in BBS1 was identified (Table 3 ). This mutation was present homozygously in the exome data with only two reads, which was further confirmed as a homozygous change with Sanger sequencing ( Figure 1C ). Segregation analysis ( Figure 1A ) revealed that the mutation was homozygous in both affected siblings, heterozygous in the parents and normal siblings, and absent in other unaffected members of the family. The c.47+1G>T variant is predicted to affect one of the canonical splice site nucleotides, which might therefore completely inactivate splice donor site. Splice site prediction software predicted inactivation of the wild-type splice donor site at the 3′ end of exon 1 and did not predict an alternative splice donor site in intron 1. The mutant messenger RNA is likely to have a premature stop codon at position 17 ( Figure  3 ).
Similarly in family B, exome data were analyzed for variants in known BBS genes that resulted in identifying a previously reported missense mutation c.442G>A; p.Asp148Asn in BBS1 ( Figure 1D ; Table 3 ). Segregation analysis ( Figure 1B ) revealed that this mutation was homozygously present in the affected individuals (IV:3 and IV:5), heterozygously carried by the healthy siblings (IV:1 and IV:2) and their mother (III:2) and absent in one healthy sister (IV:4).
Polyphen-2 predicted missense mutation p.(Asp148Asn) was "probably damaging" whereas SIFT predicted this mutation was "tolerated." HOPE predicted that the mutation is present in the core of a domain; a difference in the properties of the wild-type and mutant amino acid residues might disturb the core structure of this domain.
DISCUSSION
In the current study, we report on two consanguineous families from Pakistan, with affected individuals presenting BBS, a rare, clinically and genetically heterogeneous disorder. In approximately 75% of families with BBS, mutations are detected in known BBS genes [21] . BBS1 is the most frequently mutated BBS gene and accounts for the disease in nearly 24% of European patients with BBS [4, 29, 30] . The BBS1 mutation p.(Met390Arg) is a frequent founder mutation [5, 7, 19] found in 78.3% of families with BBS1 mutations [5, 21] . The exact function of BBS1 in the pathology of BBS is still unclear but as a part of the BBSome complex, BBS1 is thought to play a crucial role by interacting with other proteins through its beta-propeller domain [37] . A detailed model of the assembly of the BBSome complex was proposed recently [38] , which describes crucial steps required for the proper assembly of BBS proteins to form a functional BBSome complex. BBS1 joins the BBSome complex by interacting with BBS9 and BBS2, and the last component (BBS4) completes the BBSome complex assembly [38] . In the presence of the BBS1 M390R/M390R mutant protein, BBS4 fails to join the BBSome complex, which shows that protein-protein interactions between mutant BBS1 and wild-type BBS4 are lost [38] . The p.(Met390Arg) variant is a frequently occurring missense mutation in BBS1 in individuals with BBS that severely affects these normal protein-protein interactions.
The splice site mutation c.47+1G>T identified in the current study abolishes the splice site and theoretically could result in the synthesis of a truncated mutant protein In family A, the main intrafamilial phenotypic difference was the presence of polydactyly. In addition, bull's eye macular atrophy was observed only in the affected woman, which also highlights the phenotype variability. Polydactyly is a common clinical feature of BBS [18] ; the absence of polydactyly in the proband of family A could be the effect of a still unknown modifier allele. A known modifier of ciliopathies (RPGRIP1L) has been functionally tested in zebrafish to observe the modifying effects of different alleles [9] . In our family, variants were not identified in RPGRIP1L. Moreover, although we did not test the functional effect of other identified variants on phenotype, their effect on phenotypic variability cannot be ruled out. Ophthalmological examinations revealed severely reduced electrophysiological responses of rods and cones (Table 1) , and the visual acuity was restricted to hand movements only, illustrating the severity of the disease. The proband of family B had intellectual disability and did not cooperate during the electrophysiological measurements.
BBS features Present
Primary features
Contrary to our findings, in a recent study, BBS1 mutations were reported to be associated with milder ocular phenotypes compared to phenotypes associated with mutations in other BBS genes [42] . Moreover, in another study, milder non-ocular BBS phenotypes were reported in patients with mutations in BBS12 [35] . In addition, mutations in BBS1 [11] , BBS3 [43] , and BBS8 [44] have also been implicated in non-syndromic retinitis pigmentosa. In a pharmacogenomic study aberrant splicing caused by a splice donor site mutation in BBS1 (c.479G>A) was corrected in the patient's fibroblasts by using mutated U1 small nuclear RNA (snRNA) [45] . U1 snRNA is involved in the recognition of exons during splicing. The investigators generated mutant U1 snRNAs with increased complementarity for a mutated splice donor site, which were subsequently used to redirect correct splicing. Using a similar strategy, the splice donor site mutation (c.47+1G>T) identified in our study could first be assessed in in vitro studies and then in model organisms, which might then lead to the development of treatment options for individuals with this particular mutation in the future.
The missense mutation p.(Asp148Asn) was previously identified in an American and a British patient [21] ; thus, this is the second report of this mutation. Although this mutation is distributed worldwide, it is rare, being a genetic cause of the disease in only four patients.
In the absence of a solved three-dimensional structure or modeling template for the wild-type BBS1 protein, the program HOPE did not predict a three-dimensional model for the mutant protein, but based on the differences in the amino acid properties, it was predicted that wild-type interactions of the protein might be disturbed due to the introduction of a mutant residue. Although in silico analysis is a good analytical tool for assessing the pathogenicity of missense variants, functional validation is mandatory.
The use of exome sequencing to identify genetic mutations in BBS families was justified in our study when we compared the expenses of Sanger sequencing and exome sequencing. Expenditure for the Sanger sequencing (€2,140) of the coding exons (228 exons; 214 amplicons) of 17 BBS genes in both directions is comparable with the exome sequencing costs (€1,500-2,000). In addition, Sanger sequencing requires longer hands-on time and more effort compared to exome sequencing.
In conclusion, in Pakistani families with BBS, exome sequencing proved to be a successful and fast method for identifying a novel mutation and a recurrent mutation in BBS1. To our knowledge, this is the first report describing BBS1 mutations in the Pakistani population. In the future, some of the clinical features might be addressed using gene therapy, but currently, only genetic counseling is warranted for carriers of mutations. 
